• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Mitochondrial DNA Biomarker Discovery and Validation for the Detection, Prognosis and Treatment of Prostate Cancer.
【24h】

Mitochondrial DNA Biomarker Discovery and Validation for the Detection, Prognosis and Treatment of Prostate Cancer.

机译：线粒体DNa生物标志物发现和验证前列腺癌的检测，预后和治疗。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The mitochondrial genome offers excellent potential as a DNA-based biomarker for cancer detection, as most tumors are composed of cells that each share thousands of identical somatic mtDNA point mutations, a phenomenon called homoplasmy. Here we propose the use of the sensitive mutation detection assays to test whether the frequency of circulating homoplasmic mtDNA tumor mutations in patients with prostate cancer would be a specific and sensitive marker of prostatic tumor therapeutic response, progression, and recurrence. Prostate cancer presents an ideal tumor model to test this new technology, as the frequency of prostate gland biopsy, homoplasmic mtDNA mutations, recurrence following radical prostatectomy are high.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号